Brief: Celsion Corp Says Novel Gene-Mediated Immunotherapy Is Safe And Demonstrates An Acceptable Risk/Benefit

Imunon

21/06/2022 14:28

June 21 (Reuters) - Celsion Corp  CLSN.O :
    * CELSION REPORTS DATA SAFETY MONITORING BOARD UNANIMOUS
RECOMMENDATION TO CONTINUE DOSING PATIENTS IN THE PHASE II
PORTION OF THE OVATION 2 STUDY WITH GEN-1 IN ADVANCED OVARIAN
CANCER
    * CELSION CORP- NOVEL GENE-MEDIATED IMMUNOTHERAPY IS SAFE
AND
DEMONSTRATES AN ACCEPTABLE RISK/BENEFIT
    * CELSION CORP- FULL ENROLLMENT EXPECTED BY Q3 OF 2022

Source text for Eikon:  ID:nGNX4V8wzC 
Further company coverage:  CLSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))